The Autoinjectors Market size was estimated USD 0.8 billion in 2022 and is expected to reach USD 2.3 billion by 2030 at a CAGR of 14.2% during the forecast period of 2023-2030.
A syringe with a spring-charged needle and a pre-charged dosage of pharmaceuticals is referred to as an autoinjector. When forced into the body in a sliding motion, a measured dosage of a medicine is released and given. Auto-injectors have a number of benefits, including lowering the incidence of needle stick incidents and needle-related anxiety disorders.
.png)
The need for autoinjectors has also increased as chronic conditions including diabetes, rheumatoid arthritis, and multiple sclerosis are becoming more common. Autoinjectors provide a secure and reliable method of administering these drugs, which are frequently injected regularly to treat various illnesses. Around 573 million people worldwide had diabetes in 2022, according to the International Diabetes Federation (IDF), and this number is anticipated to considerably increase in the future years. The true number of persons living with diabetes may be higher than stated, according to the IDF's estimate that roughly 50% of those with the disease go undiagnosed. Since the majority of people with diabetes live in low- and middle-income countries, diabetes directly causes 1.5 million fatalities each year. So, the increasing importance of preventive care in developed and developing economies will spur autoinjectors market growth.
DRIVERS
Autoinjectors are beneficial in medical care services
Increase in the prevalence of targeted therapies
Autoinjectors offers advantages such as quicker and easier medicine administration. Anaphylactic shocks and opioid overdoses call for prompt medical attention. Food allergies, insect sting allergies, medication allergies, among others, frequently result in anaphylactic shocks that, if not treated right once, can be fatal. Epinephrine has long been regarded as the first line of anaphylaxis treatment. The portability and speedy delivery of the epinephrine autoinjectors make them advantageous for patients with a history of anaphylactic crises. Autoinjectors are therefore essential in the management of situations necessitating urgent medical attention. These benefits that autoinjectors provide should help the market growth.
RESTRAIN
Alternative modes of drug delivery such as oral, nasal among others and needle phobia
Autoinjector syringes have been used to inject medications, which is a painful delivery method. Because of this, patients and healthcare providers are increasingly focusing on alternative administration methods such the oral, nasal, and topical routes. Furthermpore, technological developments have produced injectors that don't use needles. Also, the frequency of medicine administration is high for disorders including growth hormone insufficiency, rheumatoid arthritis, and diabetes, among others. As a result, frequent injections may cause needle anxiety in patients with certain disorder, encouraging their switch to alternative drug delivery methods.
OPPORTUNITY
Increasing shift of therapy to home care setting
For several therapies, home care settings are being given more and more attention worldwide. This is supported by, among other things, improvements in medical technology, significant financial savings over hospital-based therapies, and changing patient preferences. The development of autoinjectors with technological advancements like audio-visual cues for simple handling and administration, connectivity for better assistance, and large dose and volume devices for less frequent drug administration are all supporting the adoption of autoinjectors in home care settings, thereby creating market opportunities.
CHALLENGES
Development of autoinjectors for multiple drug viscosities
The viscosity of a drug affects number of administration-related factors. Drugs can be delivered by autoinjectors at a precise volume and viscosity at a precise rate of injection. Depending on the drug's viscosity, the autoinjector's design changes. For example, spring-powered autoinjectors need springs with various physical characteristics, such as length, thickness, and composition appropriate to the viscosity of the medicine to be delivered. Since autoinjectors are customized, the one-size-fits-all principle is not appropriate. The issue in creating an auto injector that works with various viscosities is supporting various injection speeds and volumes while maintaining accuracy and safety.
The Russia-Ukraine conflict is estimated to have a moderate impact on the Autoinjectors Market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the Autoinjectors Market growth over the forecast period.
IMPACT OF ONGOING RECESSION
The impact of a recession on the market is increased competition. As organizations become more price-sensitive, they may seek Autoinjectors Market providers or technologies at a lower cost, potentially leading to price pressure and decreased profit margins for existing providers. However, the market may also be somewhat recession-resistant, as certain industries, such as healthcare and pharmaceuticals, may continue to require Autoinjectors Market services regardless of economic conditions. Additionally, as the importance of public health and safety is emphasized during times of crisis, such as a pandemic, there may be increased awareness and demand for Autoinjectors Market services and technologies.
By Product Type
Disposable
Reusable
In 2022, disposable segment is expected to dominate the autoinjectors market share of 18.9% during the forecast period owing to patient centric design, ease of usage especially patients with visual impairment, low capalbility.
By Technology
Manual Autoinjectors
Automatic Autoinjectors
By Disease Indication
Rheumatoid Arthritis
Multiple Sclerosis
Diabetes
Anaphylaxis
In 2022, the rheumatoid arthritis segment is expected to dominate the autoinjectors market growth Due to autoinjectors are devices that make it simple and accurate for patients to self-administer drugs. About 1% of the world's population suffers from rheumatoid arthritis (RA), with women being more frequently affected than men. It is a chronic autoimmune condition that hurts and inflames the joints. Antirheumatic medications (DMARDs) that affect the course of the illness can be administered using autoinjectors. Autoinjectors are advantageous for RA patients who must frequently inject their medication since they offer a more practical and effective method of doing so.
By End User
Homecare Settings
Hospitals & Clinics
Ambulatory Surgical Centers
.png)
In 2022, the homecare settings segment is expected to dominate the market share of 19.1% during the forecast period due to the increasing elderly population, the rising incidence of diabetes can be attributed to the fastest growth rate of this segment.
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSES
North America held a significant market share growth of 42% in 2022 and is likely to maintain its dominance during the forecast period due to North America autoinjector market accounted for more than 25.7 billion in 2022, Also, the region offers favorable reimbursement on use of autoinjectors. Moreover, increasing number of cases of anaphylactic shock is likely to support adoption of autoinjectors. Moreover, the developed countries of the region have high level of awareness about self-administration drug delivery devices which is anticipated to further drive the market growth in this region. According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension. The annual cost burden associated with chronic disorders in the US is around USD 3.7 trillion; this accounts for nearly 20% of the country’s GDP share
Asia-Pacific is witness to expand fastest CAGR rate of 19.3% during the forecast period owing to factors such as rising cases of diabetics and anaphylaxis due to food allergies in countries such as India, China, Japan, Singapore, & Australia.
The major key players are Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical, West Pharmaceutical Services, Inc., Recipharm AB, Haselmeier GmbH, Owen Mumford Ltd., Gerreshiemer AG, Philip-Medisize, LLC, Oval Medical Technologies Ltd., Solteam Incorporation Co., Ltd., Elcam Drug Delivery Devices (E3D), Antares Pharma, Inc., Jabil, Inc., and Others.
SHL Medical, in May 2023, the sonelokimab autoinjector was created in cooperation between SHL Medical and MoonLake Immunotherapeutics. MoonLake's Nanobody sonelokimab will be supplied clinically and maybe commercially using SHL Medical's Molly autoinjector technology.
Becton, Dickinson and Company (BD), in October 2022, BD partnered with Biocorp for Biocorp’s Injay technology, which adds connectivity to prefilled syringes. It is anticipated to aid BD in tracking adherence to self-administered injectable drugs.
| Report Attributes | Details |
| Market Size in 2022 | US$ 0.8 Bn |
| Market Size by 2030 | US$ 2.3 Bn |
| CAGR | CAGR of 14.2 % From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2019-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product Type (Disposable, Reusable) • By Technology (Manual Autoinjectors, Automatic Autoinjectors) • By Disease Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis) • By End User (Homecare Settings, Hospitals & Clinics, Ambulatory Surgical Centers) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical, West Pharmaceutical Services, Inc., Recipharm AB, Haselmeier GmbH, Owen Mumford Ltd., Gerreshiemer AG, Philip-Medisize, LLC, Oval Medical Technologies Ltd., Solteam Incorporation Co., Ltd., Elcam Drug Delivery Devices (E3D), Antares Pharma, Inc., Jabil, Inc. |
| Key Drivers | • Autoinjectors are beneficial in medical care services • Increase in the prevalence of targeted therapies |
| Market Challenges | • Development of autoinjectors for multiple drug viscosities |
Ans: According to our analysis, the Autoinjectors Market is anticipated to reach USD 2.3 billion By 2030.
Ans: The Autoinjectors Market is expected to grow at 14.2% CAGR from 2023 to 2030.
Ans: The leading participants are Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical, West Pharmaceutical Services, Inc., Recipharm AB, Haselmeier GmbH, Owen Mumford Ltd., Gerreshiemer AG, Philip-Medisize, LLC, Oval Medical Technologies Ltd., Solteam Incorporation Co., Ltd., Elcam Drug Delivery Devices (E3D), Antares Pharma, Inc., Jabil, Inc., and Others.
Ans: Factors such as the Prevalence of targeted therapies, favorable reimbursement policies and investments in the form of funds and grants for therapies associated with auto injectors accelerate the market growth.
Ans: Yes, you may request customization based on your company's needs.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Autoinjectors Market Segmentation, by Product
8.1 Disposable
8.2 Consumables
9. Autoinjectors Market Segmentation, by Technology
9.1 Manual Autoinjector
9.2 Automatic Autoinjector
10. Autoinjectors Market Segmentation, by Disease Indication
10.1 Rheumatoid Arthritis
10.2 Multiple Sclerosis
10.3 Diabetes
10.4 Anaphylaxis
11. Autoinjectors Market Segmentation, by End User
11.1 Homecare Settings
11.2 Hospitals & Clinics
11.3 Ambulatory Surgical Centers
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Autoinjectors Market by Country
12.2.2 North America Autoinjectors Market by Product Type
12.2.3 North America Autoinjectors Market by Agent
12.2.4 North America Autoinjectors Market by Disease Indication
12.2.5 North America Autoinjectors Market by End User
12.2.6 USA
12.2.6.1 USA Autoinjectors Market by Product Type
12.2.6.2 USA Autoinjectors Market by Technology
12.2.6.3 USA Autoinjectors Market by Disease Indication
12.2.6.4 USA Autoinjectors Market by End User
12.2.7 Canada
12.2.7.1 Canada Autoinjectors Market by Product Type
12.2.7.2 Canada Autoinjectors Market by Technology
12.2.7.3 Canada Autoinjectors Market by Disease Indication
12.2.7.4 Canada Autoinjectors Market by End User
12.2.8 Mexico
12.2.8.1 Mexico Autoinjectors Market by Product Type
12.2.8.2 Mexico Autoinjectors Market by Technology
12.2.8.3 Mexico Autoinjectors Market by Disease Indication
12.2.8.4 Mexico Autoinjectors Market by End User
12.3 Europe
12.3.1 Eastern Europe
12.3.1.1 Eastern Europe Autoinjectors Market by Country
12.3.1.2 Eastern Europe Autoinjectors Market by Product Type
12.3.1.3 Eastern Europe Autoinjectors Market by Technology
12.3.1.4 Eastern Europe Autoinjectors Market by Disease Indication
12.3.1.5 Eastern Europe Autoinjectors Market by End User
12.3.1.6 Poland
12.3.1.6.1 Poland Autoinjectors Market by Product Type
12.3.1.6.2 Poland Autoinjectors Market by Technology
12.3.1.6.3 Poland Autoinjectors Market by Disease Indication
12.3.1.6.4 Poland Autoinjectors Market by End User
12.3.1.7 Romania
12.3.1.7.1 Romania Autoinjectors Market by Product Type
12.3.1.7.2 Romania Autoinjectors Market by Technology
12.3.1.7.3 Romania Autoinjectors Market by Disease Indication
12.3.1.7.4 Romania Autoinjectors Market by End User
12.3.1.8 Hungary
12.3.1.8.1 Hungary Autoinjectors Market by Product Type
12.3.1.8.2 Hungary Autoinjectors Market by Technology
12.3.1.8.3 Hungary Autoinjectors Market by Disease Indication
12.3.1.8.4 Hungary Autoinjectors Market by End User
12.3.1.9 Turkey
12.3.1.9.1 Turkey Autoinjectors Market by Product Type
12.3.1.9.2 Turkey Autoinjectors Market by Technology
12.3.1.9.3 Turkey Autoinjectors Market by Disease Indication
12.3.1.9.4 Turkey Autoinjectors Market by End User
12.3.1.10 Rest of Eastern Europe
12.3.1.10.1 Rest of Eastern Europe Autoinjectors Market by Product Type
12.3.1.10.2 Rest of Eastern Europe Autoinjectors Market by Technology
12.3.1.10.3 Rest of Eastern Europe Autoinjectors Market by Disease Indication
12.3.1.10.4 Rest of Eastern Europe Autoinjectors Market by End User
12.3.2 Western Europe
12.3.2.1 Western Europe Autoinjectors Market by Country
12.3.2.2 Western Europe Autoinjectors Market by Product Type
12.3.2.3 Western Europe Autoinjectors Market by Technology
12.3.2.4 Western Europe Autoinjectors Market by Disease Indication
12.3.2.5 Western Europe Autoinjectors Market by End User
12.3.2.6 Germany
12.3.2.6.1 Germany Autoinjectors Market by Product Type
12.3.2.6.2 Germany Autoinjectors Market by Technology
12.3.2.6.3 Germany Autoinjectors Market by Disease Indication
12.3.2.6.4 Germany Autoinjectors Market by End User
12.3.2.7 France
12.3.2.7.1 France Autoinjectors Market by Product Type
12.3.2.7.2 France Autoinjectors Market by Technology
12.3.2.7.3 France Autoinjectors Market by Disease Indication
12.3.2.7.4 France Autoinjectors Market by End User
12.3.2.8 UK
12.3.2.8.1 UK Autoinjectors Market by Product Type
12.3.2.8.2 UK Autoinjectors Market by Technology
12.3.2.8.3 UK Autoinjectors Market by Disease Indication
12.3.2.8.4 UK Autoinjectors Market by End User
12.3.2.9 Italy
12.3.2.9.1 Italy Autoinjectors Market by Product Type
12.3.2.9.2 Italy Autoinjectors Market by Technology
12.3.2.9.3 Italy Autoinjectors Market by Disease Indication
12.3.2.9.4 Italy Autoinjectors Market by End User
12.3.2.10 Spain
12.3.2.10.1 Spain Autoinjectors Market by Product Type
12.3.2.10.2 Spain Autoinjectors Market by Technology
12.3.2.10.3 Spain Autoinjectors Market by Disease Indication
12.3.2.10.4 Spain Autoinjectors Market by End User
12.3.2.11 Netherlands
12.3.2.11.1 Netherlands Autoinjectors Market by Product Type
12.3.2.11.2 Netherlands Autoinjectors Market by Technology
12.3.2.11.3 Netherlands Autoinjectors Market by Disease Indication
12.3.2.11.4 Netherlands Autoinjectors Market by End User
12.3.2.12 Switzerland
12.3.2.12.1 Switzerland Autoinjectors Market by Product Type
12.3.2.12.2 Switzerland Autoinjectors Market by Technology
12.3.2.12.3 Switzerland Autoinjectors Market by Disease Indication
12.3.2.12.4 Switzerland Autoinjectors Market by End User
12.3.2.13 Austria
12.3.2.13.1 Austria Autoinjectors Market by Product Type
12.3.2.13.2 Austria Autoinjectors Market by Technology
12.3.2.13.3 Austria Autoinjectors Market by Disease Indication
12.3.2.13.4 Austria Autoinjectors Market by End User
12.3.2.14 Rest of Western Europe
12.3.2.14.1 Rest of Western Europe Autoinjectors Market by Product Type
12.3.2.14.2 Rest of Western Europe Autoinjectors Market by Technology
12.3.2.14.3 Rest of Western Europe Autoinjectors Market by Disease Indication
12.3.2.14.4 Rest of Western Europe Autoinjectors Market by End User
12.4 Asia-Pacific
12.4.1 Asia Pacific Autoinjectors Market by Country
12.4.2 Asia Pacific Autoinjectors Market by Product Type
12.4.3 Asia Pacific Autoinjectors Market by Technology
12.4.4 Asia Pacific Autoinjectors Market by Disease Indication
12.4.5 Asia Pacific Autoinjectors Market by End User
12.4.6 China
12.4.6.1 China Autoinjectors Market by Product Type
12.4.6.2 China Autoinjectors Market by Technology
12.4.6.3 China Autoinjectors Market by Disease Indication
12.4.6.4 China Autoinjectors Market by End User
12.4.7 India
12.4.7.1 India Autoinjectors Market by Product Type
12.4.7.2 India Autoinjectors Market by Technology
12.4.7.3 India Autoinjectors Market by Disease Indication
12.4.7.4 India Autoinjectors Market by End User
12.4.8 Japan
12.4.8.1 Japan Autoinjectors Market by Product Type
12.4.8.2 Japan Autoinjectors Market by Technology
12.4.8.3 Japan Autoinjectors Market by Disease Indication
12.4.8.4 Japan Autoinjectors Market by End User
12.4.9 South Korea
12.4.9.1 South Korea Autoinjectors Market by Product Type
12.4.9.2 South Korea Autoinjectors Market by Technology
12.4.9.3 South Korea Autoinjectors Market by Disease Indication
12.4.9.4 South Korea Autoinjectors Market by End User
12.4.10 Vietnam
12.4.10.1 Vietnam Autoinjectors Market by Product Type
12.4.10.2 Vietnam Autoinjectors Market by Technology
12.4.10.3 Vietnam Autoinjectors Market by Disease Indication
12.4.10.4 Vietnam Autoinjectors Market by End User
12.4.11 Singapore
12.4.11.1 Singapore Autoinjectors Market by Product Type
12.4.11.2 Singapore Autoinjectors Market by Technology
12.4.11.3 Singapore Autoinjectors Market by Disease Indication
12.4.11.4 Singapore Autoinjectors Market by End User
12.4.12 Australia
12.4.12.1 Australia Autoinjectors Market by Product Type
12.4.12.2 Australia Autoinjectors Market by Technology
12.4.12.3 Australia Autoinjectors Market by Disease Indication
12.4.12.4 Australia Autoinjectors Market by End User
12.4.13 Rest of Asia-Pacific
12.4.13.1 Rest of Asia-Pacific Autoinjectors Market by Product Type
12.4.13.2 Rest of Asia-Pacific Autoinjectors Market by Technology
12.4.13.3 Rest of Asia-Pacific Autoinjectors Market by Disease Indication
12.4.13.4 Rest of Asia-Pacific Autoinjectors Market by End User
12.5 Middle East & Africa
12.5.1 Middle East
12.5.1.1 Middle East Autoinjectors Market by country
12.5.1.2 Middle East Autoinjectors Market by Product Type
12.5.1.3 Middle East Autoinjectors Market by Technology
12.5.1.4 Middle East Autoinjectors Market by Disease Indication
12.5.1.5 Middle East Autoinjectors Market by End User
12.5.1.6 UAE
12.5.1.6.1 UAE Autoinjectors Market by Product Type
12.5.1.6.2 UAE Autoinjectors Market by Technology
12.5.1.6.3 UAE Autoinjectors Market by Disease Indication
12.5.1.6.4 UAE Autoinjectors Market by End User
12.5.1.7 Egypt
12.5.1.7.1 Egypt Autoinjectors Market by Product Type
12.5.1.7.2 Egypt Autoinjectors Market by Technology
12.5.1.7.3 Egypt Autoinjectors Market by Disease Indication
12.5.1.7.4 Egypt Autoinjectors Market by End User
12.5.1.8 Saudi Arabia
12.5.1.8.1 Saudi Arabia Autoinjectors Market by Product Type
12.5.1.8.2 Saudi Arabia Autoinjectors Market by Technology
12.5.1.8.3 Saudi Arabia Autoinjectors Market by Disease Indication
12.5.1.8.4 Saudi Arabia Autoinjectors Market by End User
12.5.1.9 Qatar
12.5.1.9.1 Qatar Autoinjectors Market by Product Type
12.5.1.9.2 Qatar Autoinjectors Market by Technology
12.5.1.9.3 Qatar Autoinjectors Market by Disease Indication
12.5.1.9.4 Qatar Autoinjectors Market by End User
12.5.1.10 Rest of Middle East
12.5.1.10.1 Rest of Middle East Autoinjectors Market by Product Type
12.5.1.10.2 Rest of Middle East Autoinjectors Market by Technology
12.5.1.10.3 Rest of Middle East Autoinjectors Market by Disease Indication
12.5.1.10.4 Rest of Middle East Autoinjectors Market by End User
12.5.2. Africa
12.5.2.1 Africa Autoinjectors Market by country
12.5.2.2 Africa Autoinjectors Market by Product Type
12.5.2.3 Africa Autoinjectors Market by Technology
12.5.2.4 Africa Autoinjectors Market by Disease Indication
12.5.2.5 Africa Autoinjectors Market by End User
12.5.2.6 Nigeria
12.5.2.6.1 Nigeria Autoinjectors Market by Product Type
12.5.2.6.2 Nigeria Autoinjectors Market by Technology
12.5.2.6.3 Nigeria Autoinjectors Market by Disease Indication
12.5.2.6.4 Nigeria Autoinjectors Market by End User
12.5.2.7 South Africa
12.5.2.7.1 South Africa Autoinjectors Market by Product Type
12.5.2.7.2 South Africa Autoinjectors Market by Technology
12.5.2.7.3 South Africa Autoinjectors Market by Disease Indication
12.5.2.7.4 South Africa Autoinjectors Market by End User
12.5.2.8 Rest of Africa
12.5.2.8.1 Rest of Africa Autoinjectors Market by Product Type
12.5.2.8.2 Rest of Africa Autoinjectors Market by Technology
12.5.2.8.3 Rest of Africa Autoinjectors Market by Disease Indication
12.5.2.8.4 Rest of Africa Autoinjectors Market by End User
12.6. Latin America
12.6.1 Latin America Autoinjectors Market by country
12.6.2 Latin America Autoinjectors Market by Product Type
12.6.3 Latin America Autoinjectors Market by Technology
12.6.4 Latin America Autoinjectors Market by Disease Indication
12.6.5 Latin America Autoinjectors Market by End User
12.6.6 Brazil
12.6.6.1 Brazil Autoinjectors Market by Product Type
12.6.6.2 Brazil Autoinjectors Market by Technology
12.6.6.3 Brazil Autoinjectors Market by Disease Indication
12.6.6.4 Brazil Autoinjectors Market by End User
12.6.7 Argentina
12.6.7.1 Argentina Autoinjectors Market by Product Type
12.6.7.2 Argentina Autoinjectors Market by Technology
12.6.7.3 Argentina Autoinjectors Market by Disease Indication
12.6.7.4 Argentina Autoinjectors Market by End User
12.6.8 Colombia
12.6.8.1 Colombia Autoinjectors Market by Product Type
12.6.8.2 Colombia Autoinjectors Market by Technology
12.6.8.3 Colombia Autoinjectors Market by Disease Indication
12.6.8.4 Colombia Autoinjectors Market by End User
12.6.9 Rest of Latin America
12.6.9.1 Rest of Latin America Autoinjectors Market by Product Type
12.6.9.2 Rest of Latin America Autoinjectors Market by Technology
12.6.9.3 Rest of Latin America Autoinjectors Market by Disease Indication
12.6.9.4 Rest of Latin America Autoinjectors Market by End User
13 Company Profile
13.1 Becton, Dickinson and Company (BD)
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products/ Services Offered
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Ypsomed Holding AG
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products/ Services Offered
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 SHL Medical
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products/ Services Offered
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 West Pharmaceutical Services Inc.
13.4 Company Overview
13.4.2 Financials
13.4.3 Products/ Services Offered
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Recipharm AB
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products/ Services Offered
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Haselmeier GmbH
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products/ Services Offered
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Owen Mumford Ltd.
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products/ Services Offered
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Gerreshiemer AG
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products/ Services Offered
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Philip-Medisize LLC
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products/ Services Offered
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Oval Medical Technologies Ltd.
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products/ Services Offered
13.10.4 SWOT Analysis
13.10.5 The SNS View
13.11 Solteam Incorporation Co., Ltd.
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products/ Services Offered
13.11.4 SWOT Analysis
13.11.5 The SNS View
13.12 Elcam Drug Delivery Devices (E3D)
13.12.1 Company Overview
13.12.2 Financials
13.12.3 Products/ Services Offered
13.12.4 SWOT Analysis
13.12.5 The SNS View
13.13 Antares Pharma, Inc.
13.13.1 Company Overview
13.13.2 Financials
13.13.3 Products/ Services Offered
13.13.4 SWOT Analysis
13.13.5 The SNS View
13.14 Jabil, Inc.
13.14.1 Company Overview
13.14.2 Financials
13.14.3 Products/ Services Offered
13.14.4 SWOT Analysis
13.14.5 The SNS View
13.15 Others
13.15.1 Company Overview
13.15.2 Financials
13.15.3 Products/ Services Offered
13.15.4 SWOT Analysis
13.15.5 The SNS View
14. Competitive Landscape
14.1 Competitive Bench marking
14.2 Market Share Analysis
14.3 Recent Developments
14.3.1 Industry News
14.3.2 Company News
14.3.3 Mergers & Acquisitions
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Viral Vectors and Plasmid DNA Manufacturing Market size was estimated USD 4.4 billion in 2022 and is expected to reach USD 19.4 billion by 2030 at a CAGR of 20.4% during the forecast period of 2023-2030.
The Ambulatory Surgical Centers Market Size was valued at USD 96.6 billion in 2023 and is expected to reach USD 137.3 billion by 2031 and grow at a CAGR of 4.5% over the forecast period 2024-2031.
The Geographic Atrophy (GA) Market is expected to grow at a CAGR of 7.2% over the forecast period 2023-2030.
In 2023, The Legionella Testing Market size amounted to USD 304.29 billion & is estimated to reach USD 624.35 billion by 2031 and increase at a compound annual growth rate of 9.4% between 2024 and 2031.
The Artificial Hip Joint market size was escalated to USD 7.27 billion by the end of 2022 and is projected to reach at USD 10.99 billion by 2030 with a growing healthy CAGR of 5.3% during the 2023-2030 period.
The Medical Laser Market size was valued at USD 5.84 Billion in 2023 and is expected to reach USD 20.22 Billion By 2031 and grow at a CAGR of 16.8% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
